Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy products for patients with compromised pulmonary function. Its core product references include the SmartVest Airway Clearance System, which combines a programmable air pulse generator, therapy garment, and connecting hose for airway clearance therapy.
Recurring ELMD news centers on quarterly financial results, revenue trends in homecare, hospital, distributor, and other channels, operating leverage, manufacturing and sales-efficiency updates, share repurchase authorizations, and investor conference participation. Company updates also discuss bronchiectasis-focused market education and the role of SmartVest within Electromed's pulmonary-care business.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Electromed, a leader in airway clearance technologies (NYSE American: ELMD), announced the participation of Kathleen Skarvan, President and CEO, and Brad Nagel, CFO, at the Inaugural EF Hutton Global Conference in New York City on May 10-11, 2023. The management team will hold one-on-one meetings on May 11, 2023, providing an opportunity for investors to learn more about Electromed's innovative airway clearance solutions, including the SmartVest® Airway Clearance System. Founded in 1992 and headquartered in New Prague, Minnesota, Electromed focuses on products that assist patients with compromised pulmonary function. For more details, visit www.smartvest.com.
Electromed, Inc. (AMEX: ELMD) will release its fiscal 2023 third quarter financial results on May 9, 2023, after market close. A conference call to discuss the results is set for the same day at 5:00 p.m. Eastern Time. Interested participants can join by calling (888) 999-5318 for domestic or (848) 280-6460 for international lines. The live webcast will be available on Electromed's Investor Relations website. For those unable to join live, a replay will be accessible via phone and online, using the provided links. Electromed specializes in airway clearance technologies, notably the SmartVest® Airway Clearance System, serving patients with compromised pulmonary function.
Electromed (NYSE American: ELMD) reported record net revenue of $11.7 million for Q2 FY 2023, reflecting a 15% increase from $10.2 million in Q2 FY 2022. Homecare revenue grew 14% year-over-year to $10.7 million. Operating income rose to $1.3 million from $1.1 million in Q2 FY 2022, while net income increased to $977,000, or $0.11 per diluted share. Gross profit was $8.68 million, comprising 74% of net revenues, despite rising material and shipping costs. The company reported cash of $6.9 million and ongoing expansion efforts in its sales force and product offerings, including the new SmartVest® Clearway® system.